Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for GNPX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 14.80M
March 31, 2026 16.93M
December 31, 2025 7.962M
September 30, 2025 0.7678M
June 30, 2025 1.391M
March 31, 2025 3.868M
December 31, 2024 1.620M
September 30, 2024 1.665M
June 30, 2024 4.346M
March 31, 2024 8.757M
December 31, 2023 7.416M
September 30, 2023 12.31M
June 30, 2023 12.05M
March 31, 2023 18.48M
December 31, 2022 22.27M
September 30, 2022 27.49M
June 30, 2022 32.41M
March 31, 2022 37.02M
December 31, 2021 41.28M
September 30, 2021 45.17M
Date Value
June 30, 2021 47.68M
March 31, 2021 50.42M
December 31, 2020 30.92M
September 30, 2020 22.98M
June 30, 2020 24.51M
March 31, 2020 23.94M
December 31, 2019 3.024M
September 30, 2019 3.531M
June 30, 2019 5.325M
March 31, 2019 7.245M
December 31, 2018 8.881M
September 30, 2018 10.48M
June 30, 2018 12.59M
March 31, 2018 -0.0419M
December 31, 2017 0.4286M
September 30, 2017 0.8715M
June 30, 2017
March 31, 2017
December 31, 2016 1.625M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics